Scientists at The Scripps Research Institute (TSRI) have given superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come. The researchers, led by Dale Boger, co-chair of TSRI’s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.

Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come. The researchers, led by Dale Boger, co-chair of TSRI's Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.

Scientists at The Scripps Research Institute (TSRI) have developed a powerful new method for finding drug candidates that bind to specific proteins. The method, reported in this week's issue of Nature, is a significant advance because it can be applied to a large set of proteins at once, even to the thousands of distinct proteins directly in their native cellular environment.

Scientists at The Scripps Research Institute (TSRI) have found a better way to achieve a chemical reaction that is used widely in the pharmaceutical as well as flavour and fragrance industries. Traditional methods of "allylic oxidation" typically employ toxic and/or expensive reagents such as chromium, ruthenium or selenium. That largely prevents the reaction from being used at industrial scales, for example to manufacture pharmaceuticals.